The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Verdence Capital Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 4.3% in the 3rd quarter, ...

Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...

The webcast will be held on November 26, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q3 2024 and provide a business update. To join the ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...